100.04
[1]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 00 Oct 15;(0):549-54.
[]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 005 Oct 1;93(8):915-3.
H30-H315-H319-H335
P1-P4-P0-P1-P80-P30+P35-P304+P340-P330-P3+P34-P405-P501
GHS0